Last updated: September 8, 2026
Odevixibat, marketed as Bylvay by Ipsen, is a rare-disease ileal bile acid transporter inhibitor used for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). Its commercial trajectory depends on expanding diagnosis in pediatric cholestatic diseases, long-term treatment duration, reimbursement, and the conversion of a narrow orphan-drug franchise into a broader rare-disease platform.
Ipsen acquired Albireo Pharma in 2023 for approximately $952 million in equity value, making Bylvay the central commercial asset in the transaction. The drug has regulatory approvals in the United States and Europe for pediatric cholestatic disorders, but its addressable market remains limited by disease rarity and diagnostic underpenetration.
What is odevixibat and how does Bylvay work?
Odevixibat is an orally administered, minimally absorbed inhibitor of the ileal bile acid transporter, also known as IBAT or ASBT. By reducing bile acid reabsorption in the terminal ileum, the drug increases fecal bile acid excretion and lowers the intrahepatic bile acid burden associated with cholestatic disease.
| Attribute |
Odevixibat |
| Brand |
Bylvay |
| Active ingredient |
Odevixibat |
| Drug class |
Ileal bile acid transporter inhibitor |
| Administration |
Oral capsule or oral pellets, depending on market and age |
| Primary diseases |
PFIC and ALGS |
| Commercial owner |
Ipsen |
| Original developer |
Albireo Pharma |
| FDA approval |
PFIC, 2021; ALGS, 2023 |
| EU approval |
PFIC, 2021; ALGS, 2023 |
| Pediatric focus |
Yes |
| Biosimilar exposure |
None; odevixibat is a small molecule |
| Main commercial substitutes |
Maralixibat, ursodeoxycholic acid, surgical diversion, liver transplantation |
Odevixibat is designed for chronic treatment. The economic value of each patient therefore depends on treatment persistence, dose escalation, payer coverage, and whether therapy delays liver transplantation or other high-cost interventions.
What diseases are approved for Bylvay?
Progressive familial intrahepatic cholestasis
The FDA approved Bylvay in July 2021 for the treatment of cholestatic pruritus due to PFIC in patients at least three months old. The approval was based on reductions in serum bile acid levels and improvements in pruritus-related outcomes in clinical studies.[1]
PFIC is a group of inherited liver diseases that impair bile formation or transport. The patient population is very small, but disease severity can be high. Many patients progress to cirrhosis, liver failure, or transplantation.
The PFIC label has commercial importance because it established Bylvay as a disease-modifying therapy in an area with few pharmacologic options. It also created an orphan-drug pricing structure with limited direct competition at launch.
Alagille syndrome
The FDA expanded Bylvay’s label in June 2023 to include cholestatic pruritus due to ALGS in patients at least 12 months old.[2] The European Commission also authorized Bylvay for ALGS in 2023.[3]
ALGS is more prevalent than PFIC but remains a rare pediatric disorder. It results from defects in the Notch signaling pathway, most often involving JAG1 or NOTCH2. Liver involvement varies substantially among patients, which creates a larger but more heterogeneous treatment population than PFIC.
The ALGS approval increased Bylvay’s commercial market and reduced dependence on PFIC alone. It also placed Bylvay in direct competition with maralixibat, marketed as Livmarli by Mirum Pharmaceuticals.
How has the odevixibat market developed?
Bylvay’s market has moved through three stages:
- Initial PFIC launch and specialist adoption.
- Expansion into ALGS.
- Commercial scaling under Ipsen after the Albireo acquisition.
The product’s revenue growth is driven less by broad primary-care prescribing than by specialist diagnosis, pediatric hepatology referrals, genetic testing, and reimbursement approvals.
Odevixibat commercial trajectory
Ipsen’s public reporting indicates that Bylvay became a growing rare-disease product after the Albireo acquisition. The company has not presented Bylvay as a mass-market medicine. Its value rests on high annual treatment revenue per patient and expansion across multiple rare cholestatic indications.
| Period |
Commercial development |
| 2021 |
FDA approval for PFIC; European authorization for PFIC |
| 2022 |
Early commercial expansion in PFIC |
| January 2023 |
Ipsen announces acquisition of Albireo |
| 2023 |
FDA and European expansion into ALGS |
| 2024 onward |
Broader Ipsen commercialization, increased diagnosis and payer activity |
The acquisition gave Ipsen direct control over global commercialization, regulatory strategy, manufacturing coordination, and lifecycle management. It also shifted Bylvay from a development-stage biotech product into a core rare-disease franchise.
How much revenue does Bylvay generate?
Bylvay sales have grown rapidly from a small launch base, but exact product-level figures vary by reporting period and exchange-rate presentation. Ipsen reports Bylvay within its specialty-care and rare-disease portfolio, while historical Albireo disclosures used different accounting periods and geographic definitions.
The financial profile has four defining characteristics:
- High revenue per treated patient.
- Low absolute patient volume.
- Significant dependence on reimbursement and patient-identification programs.
- High operating leverage after regulatory approval and commercial infrastructure buildout.
Ipsen’s acquisition price of roughly $952 million established a high commercial hurdle. The transaction required Bylvay to generate durable growth beyond its initial PFIC market. The ALGS approval was central to that thesis.[4]
Revenue drivers
Odevixibat revenue is primarily affected by:
| Driver |
Effect on Bylvay |
| New diagnosis |
Expands the treated population |
| Genetic testing |
Improves identification of PFIC and ALGS patients |
| Treatment persistence |
Increases lifetime revenue per patient |
| Dose escalation |
Raises revenue per patient but can increase payer scrutiny |
| Reimbursement |
Determines speed of prescription conversion |
| Liver transplantation |
Treatment may delay or reduce the need for transplantation in some patients |
| Geographic expansion |
Adds patients outside the United States and major European markets |
| Competition |
Limits price and share growth, especially in ALGS |
The principal financial risk is not loss of a large primary-care market. It is slower-than-expected patient identification and payer friction in a population that is clinically difficult to diagnose.
How does Bylvay compare with Livmarli?
Livmarli, or maralixibat, is Bylvay’s most important direct competitor. Both products inhibit the ileal bile acid transporter and target cholestatic pruritus in pediatric rare diseases.
| Category |
Bylvay |
Livmarli |
| Active ingredient |
Odevixibat |
Maralixibat |
| Company |
Ipsen |
Mirum Pharmaceuticals |
| PFIC approval |
Yes |
Yes, depending on jurisdiction and indication |
| ALGS approval |
Yes |
Yes |
| Administration |
Oral |
Oral |
| Mechanism |
IBAT inhibition |
IBAT inhibition |
| Competitive position |
Broader rare-disease platform under Ipsen |
Focused rare-disease franchise under Mirum |
| Key commercial issue |
Patient expansion and treatment persistence |
Share capture in ALGS and cholestatic disease |
The two drugs compete on clinical data, dosing convenience, tolerability, payer contracting, patient-support services, and physician familiarity. Because both target very small populations, a modest difference in diagnosis, label wording, or reimbursement can materially affect market share.
Odevixibat may benefit from its PFIC positioning and Ipsen’s larger commercial infrastructure. Maralixibat has established commercial presence in ALGS and other cholestatic indications. The competitive balance will depend on label breadth, treatment response, safety management, and evidence showing benefit beyond itch reduction.
What is the FDA regulatory status of Bylvay?
Bylvay is FDA-approved for:
- Cholestatic pruritus due to PFIC in patients three months of age and older.
- Cholestatic pruritus due to ALGS in patients one year of age and older.[1,2]
The product has orphan-drug positioning in both diseases. The FDA approvals were based on clinical studies measuring pruritus and bile acid-related endpoints. The label includes safety monitoring requirements associated with gastrointestinal effects, liver-related laboratory abnormalities, and potential effects on fat-soluble vitamin absorption.
Regulatory expansion opportunities include additional pediatric age groups, broader cholestatic diseases, and claims associated with delaying transplantation or improving disease progression. Such expansion would require supportive clinical evidence and may not receive the same regulatory treatment as the original orphan indications.
What patents protect odevixibat and when could generic entry occur?
Odevixibat is a small molecule, so its long-term exclusivity depends on patents, regulatory exclusivity, and litigation outcomes rather than biosimilar law.
The relevant protection categories include:
- Composition-of-matter patents covering odevixibat or related chemical classes.
- Solid-state and salt-form patents.
- Pharmaceutical-composition patents.
- Pediatric dosage and administration patents.
- Method-of-use patents covering PFIC, ALGS, cholestatic pruritus, or bile-acid disorders.
- Manufacturing and process patents.
Patent protection is expected to extend beyond the initial regulatory exclusivity period through the late 2020s and into the 2030s for selected claims, depending on jurisdiction, patent-term adjustment, patent-term extension, and the validity of later-filed formulation or method patents.
United States Orange Book and Paragraph IV risk
As an FDA-approved small molecule, Bylvay can become subject to an abbreviated new drug application and Paragraph IV patent challenge after the relevant statutory timing permits generic filing. A generic applicant would typically challenge listed patents by asserting that the patent is invalid, unenforceable, or not infringed.
The commercial risk is likely to develop in stages:
| Stage |
Risk to Ipsen |
| No ANDA filing |
Low immediate generic risk |
| Paragraph IV notice |
Litigation and potential launch uncertainty |
| Patent litigation |
Entry timing depends on court outcome and settlement |
| Patent settlement |
Potential licensed or restricted entry date |
| First generic launch |
Price erosion and payer substitution |
| Multiple generics |
Accelerated price and volume pressure |
For Bylvay, formulation and pediatric-use patents may be commercially important because the patient population includes very young children and requires age-appropriate administration. A generic product that is technically equivalent but less convenient to administer could face adoption barriers, although payers may still favor lower cost.
What biosimilar risk exists for odevixibat?
There is no biosimilar risk because odevixibat is a chemically synthesized small molecule. The relevant future threat is generic competition through the ANDA pathway.
This distinction matters financially. Generic entry can produce faster price erosion than biosimilar competition in many rare-disease markets, particularly if the generic is therapeutically substitutable and included on preferred payer formularies.
The timing of generic erosion will depend on:
- The earliest enforceable patent expiry.
- Whether pediatric formulation patents survive challenge.
- Whether an ANDA filer receives first-filer exclusivity.
- The number of generic entrants.
- State substitution rules and payer policies.
- The extent to which physicians continue to prescribe the branded product for complex pediatric patients.
Which companies are challenging or competing with Ipsen?
The competitive landscape is concentrated.
Mirum Pharmaceuticals
Mirum is the principal direct competitor through Livmarli. Its commercial strategy targets rare cholestatic liver diseases, particularly ALGS and PFIC-related markets. Mirum’s presence increases payer leverage and gives physicians an alternative IBAT inhibitor.
Generic manufacturers
Generic companies are potential long-term challengers once regulatory and patent barriers permit ANDA submissions. The small patient population may limit the number of viable entrants, but high branded pricing can create sufficient incentive for specialized generic manufacturers.
Transplant centers and surgical treatment
Liver transplantation is not a direct pharmaceutical competitor, but it is a major alternative in severe disease. If Bylvay delays transplantation, it may generate substantial clinical and economic value. If patients progress rapidly despite treatment, the product’s perceived value may be lower.
How strong is the odevixibat patent estate?
The patent estate has commercial strength when viewed as a layered portfolio rather than as a single composition patent. The strongest protection is typically the earliest valid composition-of-matter claim. Later formulation and method-of-use patents can extend practical protection, but they are more vulnerable to validity and infringement challenges.
Strengths
- Orphan-disease positioning limits the initial number of competitors.
- Pediatric formulations may create technical barriers.
- Multiple disease-specific uses can support separate patent claims.
- Ipsen has greater resources than the original developer for patent litigation and lifecycle management.
- Treatment is chronic, which increases the value of maintaining branded market share.
Weaknesses
- Small-molecule products are generally exposed to ANDA filings.
- Method-of-use claims may be easier to design around than composition claims.
- The small patient population can limit the commercial value of prolonged patent litigation.
- Competing IBAT inhibitors reduce dependence on a single branded product.
- Payers can apply pressure despite orphan status.
The practical strength of the estate will depend on the exact claims listed in the FDA’s Orange Book, patent-term adjustments, any patent-term extension, and the outcome of future Paragraph IV litigation.
What licensing and acquisition deals affect odevixibat?
The most important transaction is Ipsen’s acquisition of Albireo Pharma. Ipsen agreed to acquire Albireo for approximately $952 million in January 2023. The transaction included Albireo’s commercial products, development programs, intellectual property, and rights related to Bylvay.[4]
The deal changed the financial and strategic profile of odevixibat:
- Ipsen replaced Albireo as the primary commercial owner.
- Bylvay gained access to a larger international sales organization.
- Development and regulatory resources expanded.
- The drug became part of Ipsen’s rare-disease portfolio.
- Ipsen assumed the need to recover a substantial acquisition investment.
The acquisition also reduced the likelihood that Bylvay would be licensed piecemeal across major markets. A single global owner can coordinate pricing, evidence generation, and patent strategy more efficiently, though it also concentrates commercial risk at Ipsen.
What generic launch scenarios exist for Bylvay?
Scenario 1: Delayed generic entry
A composition patent or enforceable formulation patent survives through the early 2030s. Ipsen continues to expand diagnosis and retains high net pricing.
Scenario 2: First generic after settlement
An ANDA filer reaches a settlement permitting entry before the latest patent expiry. Bylvay retains meaningful volume but faces lower net pricing and contracting pressure.
Scenario 3: At-risk generic launch
A generic company launches before final resolution of patent litigation. Ipsen seeks damages and injunctive relief, while payers determine whether to substitute the product.
Scenario 4: Limited generic participation
Only one or two manufacturers enter because the patient population is small and manufacturing, clinical packaging, or distribution requirements are specialized. Price erosion is slower than in high-volume primary-care markets.
The most likely commercial outcome in a rare pediatric disease is a gradual erosion rather than an immediate collapse, provided Ipsen maintains physician relationships, patient-support services, and clinical evidence.
What is the revenue exposure for Ipsen?
Bylvay is strategically important but remains smaller than Ipsen’s largest established franchises. Its value comes from growth potential, rare-disease margins, and portfolio diversification rather than current scale alone.
Ipsen’s revenue exposure is concentrated in:
- PFIC and ALGS treatment uptake.
- United States reimbursement.
- European market access.
- Long-term pediatric treatment persistence.
- The ability to expand into additional cholestatic conditions.
- Competition from Livmarli.
- Patent timing and generic substitution.
A slowdown in Bylvay growth would not threaten Ipsen’s overall business in the same way a decline in a major oncology or endocrinology product would. It would, however, reduce the expected return on the Albireo acquisition and weaken Ipsen’s rare-disease growth narrative.
Key Takeaways
- Odevixibat is marketed as Bylvay by Ipsen and is approved for PFIC and ALGS.
- The drug is a chronic oral IBAT inhibitor for pediatric cholestatic pruritus.
- Ipsen acquired Albireo in 2023 for approximately $952 million, placing Bylvay at the center of its rare-disease strategy.
- The main direct competitor is maralixibat, marketed as Livmarli by Mirum Pharmaceuticals.
- Generic, rather than biosimilar, competition is the relevant long-term threat.
- Bylvay’s commercial growth depends on diagnosis, reimbursement, treatment persistence, and geographic expansion.
- Patent protection is layered across composition, formulation, dosage, method-of-use, and manufacturing claims.
- The primary financial risk is slower market expansion, not immediate loss of a broad primary-care franchise.
- The strongest upside case requires sustained ALGS uptake and expansion into additional cholestatic indications.
- The principal downside case is competitive share loss to Livmarli followed by Paragraph IV-driven generic entry.
FAQs
Is odevixibat a biologic or a small molecule?
Odevixibat is a chemically synthesized small molecule. It is not a biologic and therefore faces generic-drug risk rather than biosimilar risk.
Who owns Bylvay?
Ipsen owns and commercializes Bylvay after acquiring Albireo Pharma in 2023.
What is the main competitor to Bylvay?
Livmarli, containing maralixibat and marketed by Mirum Pharmaceuticals, is the main direct competitor.
Can Bylvay delay liver transplantation?
Clinical use may delay transplantation for some patients by reducing cholestatic burden and pruritus, but Bylvay is not a substitute for transplantation in every patient. The effect depends on disease subtype, treatment response, and progression.
Does Bylvay have orphan-drug exclusivity?
Bylvay received orphan-disease regulatory treatment for rare cholestatic indications. Orphan exclusivity operates separately from patent protection and does not prevent all forms of competition, particularly products that receive approval for a different indication or are not considered the same drug under applicable law.
References
- U.S. Food and Drug Administration. (2021). FDA approves first treatment for children with rare liver disease.
- U.S. Food and Drug Administration. (2023). FDA approves treatment for cholestatic pruritus in patients with Alagille syndrome.
- European Medicines Agency. (2023). Bylvay: EPAR product information.
- Ipsen. (2023). Ipsen completes acquisition of Albireo.
- Ipsen. (2024). Universal registration document and annual financial report.
- Mirum Pharmaceuticals. (2024). Livmarli prescribing information.
